A STUDY ON MICROBIOLOGICAL PROFILE AND SUSCEPTIBILITY PATTERN OF VAGINAL INFECTIONS AMONG WOMEN ATTENDING A TERTIARY CARE GYNECOLOGY CLINIC
DOI:
https://doi.org/10.67145/a665xq09Keywords:
Vaginal infections, Vaginal discharge, Microbiological profile, Candida albicans, Antimicrobial susceptibility, GynecologyAbstract
Background: Vaginal infections are among the most common gynecological conditions affecting women of reproductive age. They may result from bacterial, fungal, or protozoal pathogens and are frequently associated with vaginal discharge, itching, irritation, and foul-smelling discharge. Identification of the causative microorganisms and their antimicrobial susceptibility patterns is essential for appropriate treatment and prevention of recurrent infections.
Aim and Objectives: To study the microbiological profile of vaginal infections among women attending a tertiary care gynecology clinic and determine the antimicrobial susceptibility patterns of bacterial isolates.
Materials and Methods: The present observational study included 55 women attending the gynecology outpatient department with symptoms suggestive of vaginal infection. Relevant demographic and clinical details were recorded. Vaginal swabs were collected under aseptic precautions and processed using standard microbiological techniques. Microscopic examination, culture, identification of bacterial and fungal isolates, and antimicrobial susceptibility testing were performed using appropriate laboratory methods.
Results: Among the 55 women investigated, 12 (21.8%) showed microbiological positivity, whereas 43 (78.2%) were culture negative. The majority of participants belonged to the 26–35-year age group (40%). Vaginal discharge was the most frequently reported symptom (78.2%), followed by vaginal itching (58.2%). Among the 12 positive isolates, Candida albicans was the predominant organism (33.3%), followed by Escherichia coli (25%), Klebsiella pneumoniae (16.7%), Staphylococcus aureus (8.3%), Enterococcus species (8.3%), and Group B Streptococcus (8.3%). Bacterial isolates constituted 66.7%, while fungal isolates accounted for 33.3% of positive isolates.
Conclusion: The study highlights the microbiological diversity of vaginal infections among women attending a tertiary care gynecology clinic. Candida species and bacterial pathogens constituted the major isolates. Microbiological investigation and antimicrobial susceptibility testing can help guide appropriate treatment and reduce empirical antimicrobial use.
References
1.Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol. 2012;66:371-89.
2.Martin DH. The microbiota of the vagina and its influence on women's health and disease. Am J Med Sci. 2012;343(1):2-9.
3.Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol. 2015;6:81.
4.Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22.
5.Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29(2):297-301.
6.Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961-71.
7.Centers for Disease Control and Prevention. Vulvovaginal candidiasis. In: Sexually transmitted infections treatment guidelines, 2021. Atlanta: CDC; 2021.
8.Spiegel CA, Amsel R, Holmes KK. Diagnosis of bacterial vaginosis by direct Gram stain of vaginal fluid. J Clin Microbiol. 1983;18(1):170-7.
9.Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
10.Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203-11.
11.Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.
12.Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4680-7.
13.Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic JP, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG. 2011;118(5):533-49.
14.White BA, Creedon DJ, Nelson KE, Wilson BA. The vaginal microbiome in health and disease. Trends Endocrinol Metab. 2011;22(10):389-95.
15.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 34th ed. CLSI supplement M100. Wayne (PA): CLSI; 2024.
16.Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts. 3rd ed. CLSI supplement M27M44S. Wayne (PA): CLSI; 2022.
17.Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4680-7.
18.Petrova MI, Reid G, Vaneechoutte M, Lebeer S. Lactobacillus iners: friend or foe? Trends Microbiol. 2017;25(3):182-91.
19.Ma ZS, Li L. Quantifying the human vaginal community state types (CSTs) with the species specificity index. PeerJ. 2017;5:e3366.
20.Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22.
21.Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
22.World Health Organization. Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts). Geneva: WHO; 2024
23.Muzny CA, Schwebke JR. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. J Infect Dis. 2016;214 Suppl 1:S1-5.
24.Onderdonk AB, Delaney ML, Fichorova RN. The human microbiome during bacterial vaginosis. Clin Microbiol Rev. 2016;29(2):223-38.
25.World Health Organization. Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2015.
26.Centers for Disease Control and Prevention. Core elements of hospital antibiotic stewardship programs. Atlanta: CDC; 2019.
27.R. Sujatha, Nashra Afaq, Deepak Sameer. To Study the In Vitro Antifungal Susceptibility of Candida albicans and Non-Albicans Candida Species Isolated from Different Clinical Samples at a Tertiary Care Setup, Kanpur. Rama Univ J Med Sci. 2022;8(3):1–4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Population Therapeutics and Clinical Pharmacology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.